896100-81-5

Basic information

• Product Name: 4-hydroxyphenyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyde
• Synonyms: 4-hydroxyphenyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyde
• CAS NO: 896100-81-5
• Molecular Weight: 632.753
• Mol File: 896100-81-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-hydroxyphenyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxyphenyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyde(896100-81-5)
• EPA Substance Registry System: 4-hydroxyphenyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyde(896100-81-5)

Safety Data

• Hazardous Substances Data: 896100-81-5(Hazardous Substances Data)

Upstream product

• 97-30-3 methyl-alpha-D-glucopyranoside 
• 100-39-0 benzyl bromide 
• 80300-30-7 1-O-acetyl-2,3,4,6-tetra-O-benzyl-D-glucopyranose 
• 123-31-9 hydroquinone 
• 4291-69-4 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 
• 3879-79-6 methyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranoside 
• 90357-89-4 2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl trichloroacetimidate 
• 74808-09-6 2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl trichloroacetimidate 

Downstream Products

• 497-76-7 4-hydroxyphenyl α-D-glucopyranoside 

Relevant articles and documents

Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease

Despite the rapidly increasing number of patients suffering from type 2 diabetes, Alzheimer's disease, and diabetes-induced dementia, there are no disease-modifying therapies that are able to prevent or block disease progress. In this work, we investigate the potential of nature-inspired glucosylpolyphenols against relevant targets, including islet amyloid polypeptide, glucosidases, and cholinesterases. Moreover, with the premise of Fyn kinase as a paradigm-shifting target in Alzheimer's drug discovery, we explore glucosylpolyphenols as blockers of Aβ-induced Fyn kinase activation while looking into downstream effects leading to Tau hyperphosphorylation. Several compounds inhibit Aβ-induced Fyn kinase activation and decrease pTau levels at 10 μM concentration, particularly the per-O-methylated glucosylacetophloroglucinol and the 4-glucosylcatechol dibenzoate, the latter inhibiting also butyrylcholinesterase and β-glucosidase. Both compounds are nontoxic with ideal pharmacokinetic properties for further development. This work ultimately highlights the multitarget nature, fine structural tuning capacity, and valuable therapeutic significance of glucosylpolyphenols in the context of these metabolic and neurodegenerative disorders.

REAGENTS AND METHODS FOR GLYCOSYLATION

The invention provides methods and regents for the glycosylation of organic molecules. In one aspect, the invention provides a method for glycosylating a hydroxyl-containing organic compound (i.e., a glycosyl acceptor) comprising contacting a glycosyl don